Pathology

Digital Pathology Market Size Worth USD 2,271.3 Million in 2030 | Emergen Research

Retrieved on: 
Tuesday, February 28, 2023
Diabetes, Biotechnology, Nikon, Cancer, Danaher Corporation, Philips, Olympus Corporation, Diagnosis, Pathology, GE HealthCare, Physician, Heart, Hospital, Cardiovascular disease, Maintenance, Software, Privacy, Risk, Pressure, Research, Algorithm, Health information management, Marie Cassidy, MRI, Leica Biosystems, Growth, Face, Digital, Conditional sentence, Roche, Communication, USD, Prevalence, Developed country, Medical imaging

Digital Pathology Market Major Companies:

Key Points: 
  • Digital Pathology Market Major Companies:
    The digital pathology market is rapidly expanding, and several major players are competing for market share.
  • With the launch of the Aperio AT2 DX digital pathology scanner, Leica Biosystems aims to capture a larger share of the digital pathology market.
  • With the launch of the VENTANA DP 200 digital pathology system, Roche Diagnostics aims to consolidate its position as a leading player in the digital pathology market.
  • Emergen Research has segmented the global digital pathology market on the basis of product, application, end-use, and region

BioAI Health Announces the Appointment of Martin Baatz, PhD, as Chief Operating Officer

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Doctor of Philosophy, Medicine, Cancer, Health, Pathology, Biomarker, AI, Growth, AstraZeneca, Multimedia, Medical imaging, Management, Pharmaceutical industry

MANCHESTER, N.H., Feb. 28, 2023 /PRNewswire/ -- BioAI Health, an emerging leader in the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, today announced the appointment of Martin Baatz, PhD, as Chief Operating Officer of the company. In this role, Baatz will be deeply involved in scaling the company's growth and global business operations. 

Key Points: 
  • MANCHESTER, N.H., Feb. 28, 2023 /PRNewswire/ -- BioAI Health, an emerging leader in the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, today announced the appointment of Martin Baatz, PhD, as Chief Operating Officer of the company.
  • Prior to his role at BioAI, he served as Chief Commercialization Officer at Panakeia Technologies, Ltd, London.
  • I have observed BioAI Health since its foundation and I am really impressed by the development of the company and the business.
  • BioAI Health is a leading provider of multimodal AI for digital health in precision medicine.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target

Retrieved on: 
Tuesday, February 28, 2023
Medicine, Death, Parasitism, Maharashtra University of Health Sciences, Data, Malaria, Doctor of Philosophy, MD, Family, Pathology, Disease, Partnership, IND, Parasitemia, Research, Biological life cycle, Apoptosis, Patent, RI, Artemisinin, Human, Antibody, Medical laboratory, Ocean Biomedical, Vaccine, Pharmaceutical industry, Nature

Providence, RI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder and member of the board of directors Dr. Jonathan Kurtis, MD, PhD, has been awarded a new patent for his discovery related to malaria, a third parasite target called PfCDPK-5 that can potentially be used to interdict the parasite at multiple stages in the malaria cycle. This discovery builds on Dr. Kurtis’ previous discoveries that have defined the powerful roles of PfGARP and PfSEA in controlling the malaria parasite’s ability to replicate and grow within its human host. The latest patent is for the discovery that demonstrates the role of antibodies to PfCDPK-5 in preventing merozoites from escaping infected red blood cells and thus attenuates parasite multiplication in the bloodstream.

Key Points: 
  • If combined with the new target PfCDPK-5 and PfSEA, the vaccine has the potential to shut down the parasite at multiple points in its cycle.
  • In coming months, Dr. Kurtis will work to optimize the formulation of his vaccine prior to IND submission and first in humans testing.
  • This medicine will be an additional focus of Ocean Biomedical’s development pipeline in 2023 and will address a massive unmet need.
  • “Falciparum malaria is a leading cause of death in children world-wide and our global malaria treatment strategy relies almost exclusively on artemisinin-based drugs.

Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, American College, Pharmacology, Therapy, American College of Cardiology, Hypertrophic cardiomyopathy, Cardiovascular disease, Relaxation, Pathology, HCM, Edgewise, Pharmaceutical industry, Medicinal plants

The conference will take place at the New Orleans Ernest N. Morial Convention Center from March 4-6, 2023.

Key Points: 
  • The conference will take place at the New Orleans Ernest N. Morial Convention Center from March 4-6, 2023.
  • “EDG-7500 is a novel investigational therapy for the treatment of HCM with a differentiated mechanism of action,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics.
  • “The EDG-7500 data to-date has demonstrated improvements in meaningful cardiovascular disease pathophysiologies across multiple translatable preclinical disease models of HCM.
  • Importantly, EDG-7500 has shown potent gradient reduction, normalization of hyperdynamic contractility, and significant improvements in ventricular filling in our preclinical studies.

Canon Medical Extends Clinically Intelligent AI-driven Enterprise Platform to include Pathology Through Partnership with Tribun Health

Retrieved on: 
Tuesday, February 28, 2023
Enterprise imaging, Cardiology, Enterprise, Diagnosis, Endoscopy, KLAS, Partnership, Canon Medical Systems Corporation, Radiology, Marie Cassidy, Patient, Informatics, Oncology, Pathology, Medical imaging, Medical device

MINNETONKA, Minn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Canon Medical Informatics, Inc. has extended its Enterprise Imaging (EI) suite of solutions to include pathology through its partnership with Tribun Health.

Key Points: 
  • MINNETONKA, Minn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Canon Medical Informatics, Inc. has extended its Enterprise Imaging (EI) suite of solutions to include pathology through its partnership with Tribun Health.
  • This provides new capability for healthcare organizations to efficiently include pathology into their enterprise imaging plans as part of their precision informatics roadmaps.
  • Canon Medical offers healthcare organizations an all in one suite of solutions and one comprehensive partnership for your most imaging-intensive departments, such as radiology, cardiology, endoscopy, and now pathology.
  • Tribun Health’s KLAS-leading CaloPix solution was the perfect intelligent extension with same cultural fit to Canon Medical and its solutions and services.

CodaMetrix Closes $55M Series A to Autonomously Power Medical Coding, Boost Health System Revenue Cycles

Retrieved on: 
Monday, February 27, 2023
Population health, CPT, Mass General Brigham, ICD, Cloud computing, Massachusetts General Hospital, University, Classification, FCV, Organization, Association of British HealthTech Industries, Partnership, Research, Gastroenterology, Health information management, Radiology, Automation, AI, Veteran, Clinical coder, Electronic health record, Health, Pathology, Artificial intelligence, Machine learning, Medicine, Mass, Natural language processing, Henry Ford Health, Deep learning, Language, Hospital, Physician, Medical device, Nursing, Pharmaceutical industry, Diagnosis

Held largely by older Gen X-ers and Baby Boomers , medical coding needs have been outpacing the speed of healthcare innovation.

Key Points: 
  • Held largely by older Gen X-ers and Baby Boomers , medical coding needs have been outpacing the speed of healthcare innovation.
  • As it stands today, medical coding is still a highly manual and error-prone process that plagues hospital finances and contributes to physician burnout.
  • "To address these challenges, medical coding, as the proxy for evidence of care provided, has to become largely autonomous.
  • "Frustrated by the lack of quality autonomous solutions out there, we built CodaMetrix through the lens of healthcare revenue cycle experts, addressing real health system and physician concerns.

Clarapath Acquires Crosscope and Combines Tissue Processing Robotics with AI Powered Digital Pathology for Building the Lab of the Future

Retrieved on: 
Monday, February 27, 2023
Workflow, Artificial intelligence, Software, Acquisition, Entrepreneurship, Architecture, Marie Cassidy, Pathology, Robotics, Machine learning, ML, Medical imaging

Crosscope is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence (AI) and machine learning (ML) technology to assist pathologists with better and faster decision-making.

Key Points: 
  • Crosscope is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence (AI) and machine learning (ML) technology to assist pathologists with better and faster decision-making.
  • The software provides end-to-end digital pathology, and advanced, integrated, and highly flexible workflow features with an open and scalable architecture.
  • The acquisition includes a highly talented team with experience in AI, pathology, and medical software development that will join the Clarapath organization.
  • Added Dr. Jayendra Shinde, Co-Founder and CEO of Crosscope, "We are looking forward to what this combination represents as a new era for pathology, building a true fully-automated, digital, anatomic pathology laboratory solution."

Lunit and Agfa Announce Lunit INSIGHT CXR's Integration in Agfa's MUSICA® Workstation; Demonstration and Presentation to be Showcased at ECR 2023

Retrieved on: 
Monday, February 27, 2023
Pneumothorax, Congress, Patient safety, Mammography, ECR, Hospital, CXR, Workload, Pleural effusion, Patient, Abstract, Fluoroscopy, AI, Radiology, Pneumoperitoneum, European, Pathology, AUC, Communication, Tuberculosis, Medical imaging, Medical device, Agfa-Gevaert

SEOUL, South Korea, Feb. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) and Agfa Radiology Solutions today announced the integration of Lunit's AI solution for chest radiology, Lunit INSIGHT CXR, in the MUSICA® Workstation.

Key Points: 
  • SEOUL, South Korea, Feb. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) and Agfa Radiology Solutions today announced the integration of Lunit's AI solution for chest radiology, Lunit INSIGHT CXR, in the MUSICA® Workstation.
  • Agfa will showcase a demonstration of the integrated product at the upcoming European Congress of Radiology (ECR) 2023, to be held in Vienna, Austria, on March 1-5.
  • Lunit also announced that it will showcase a poster presentation highlighting Lunit INSIGHT CXR's ability to differentiate between normal and abnormal chest radiographs—one of 6 presentations Lunit will be delivering at ECR 2023.
  • Lunit will showcase a total of 6 abstracts at this year's ECR meeting, with 4 oral presentations and 2 poster presentations.

Genomics England deploys Sectra's enterprise imaging solution in groundbreaking cancer data program

Retrieved on: 
Monday, February 27, 2023
ID, Cancer, DNA, Genomics, KLAS, Whole genome sequencing, Laboratory, Research, Radiology, NHS, Google Images, Patient, Caldicott guardian, VNA, Confidentiality, Pathology, International, Medical imaging, Pharmaceutical industry, Sectra AB, Genomics England

LINKÖPING, Sweden, Feb. 27, 2023 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has now deployed its enterprise imaging system at Genomics England.

Key Points: 
  • LINKÖPING, Sweden, Feb. 27, 2023 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has now deployed its enterprise imaging system at Genomics England.
  • In particular, the solution will allow Genomics England to incorporate NHS imaging data, while the Sectra Image Exchange Portal, a system used nationally in the NHS, will also allow it to transport images from participating NHS trusts.
  • Dr Prabhu Arumugam, Director of Clinical Data and Imaging, and Caldicott Guardian for Genomics England, says: "This program will push the boundaries of cancer research and how we work.
  • Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs.

CAP Marks 10+ Years in Ensuring Quality NGS Testing

Retrieved on: 
Thursday, February 23, 2023
Research, Other Health, General Health, Technology, Infectious Diseases, Continuing, University, Health Technology, Education, Science, Biotechnology, Other Technology, Health, NGS, Clinical, American College, CAP, CDC, Pathology, AMP, Organization, PT, Partnership, American College of Medical Genetics and Genomics, FDA, CLSI, Guideline, Accreditation, Medical genetics, Korea Disease Control and Prevention Agency, ACMG, Exome, Personalized medicine, Food, Food and Drug Administration, Medical device, MD, Genomics

Precision medicine continues to gain momentum from the laboratory benchtop to the patient's bedside, with the CAP leading—as it has for over 10 years—in improving quality of next-generation sequencing (NGS) testing through laboratory accreditation and proficiency testing (PT) programs.

Key Points: 
  • Precision medicine continues to gain momentum from the laboratory benchtop to the patient's bedside, with the CAP leading—as it has for over 10 years—in improving quality of next-generation sequencing (NGS) testing through laboratory accreditation and proficiency testing (PT) programs.
  • “The CAP was the first accrediting organization in the U.S. to publish accreditation requirements specific to NGS to address its emerging use in diagnostic testing,” explained CAP President Emily E. Volk, MD, FCAP, adding that over 10 years ago, the NGS requirements were published in the 2012 Edition of the CAP Molecular Pathology checklist.
  • The CAP is also working with the CDC to develop standards related to NGS testing.
  • CAP launched its first wet specimen NGS germline PT program in 2015; somatic solid tumor and hematologic NGS PT programs were added in 2016.